Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Last updated: February 4, 2025
Sponsor: University of Wisconsin, Madison
Overall Status: Active - Recruiting

Phase

1/2

Condition

Prostate Disorders

Prostate Cancer, Early, Recurrent

Urologic Cancer

Treatment

Fianlimab

Degarelix

Nivolumab

Clinical Study ID

NCT04989946
UW21015
P50CA269011-01A1
A534260
Protocol Version 7/5/2024
Protocol Version 5/12/2023
W81XWH2110270
Protocol Version 11/11/2022
Protocol Version 10/25/2021
2021-0575
  • Ages > 18
  • Male

Study Summary

The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly diagnosed prostate cancer scheduled to undergo prostatectomy. Patients without evidence of metastatic disease, with tissue remaining from a pre-treatment biopsy, and who are being considered for standard treatment by prostatectomy, will be invited to participate and will be on study for up to 15 months.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate

  • Patients must be considered candidates for prostatectomy as per standard of care

  • High-risk patients for recurrent disease, with high risk defined based on one of thefollowing criteria:

  • Gleason score 7 and baseline serum prostate specific antigen (PSA) > 20 ng/mL

  • Gleason score > 7

  • Life expectancy of at least 12 months at screening

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  • Adequate hematologic, renal and liver function as evidenced by the following within 4 weeks of day 1:

  • Absolute neutrophil count (ANC) > 1000 / mm3

  • HgB > 9.0 gm/dL independent of transfusion

  • Platelets > 100,000 / mm3

  • Creatinine < 2.0 mg/dL

  • Aspartate aminotransferase (AST), Alanine transaminase (ALT) < 2.5 xinstitutional upper limit of normal (ULN)

  • Total bilirubin < 2x institutional ULN (NOTE: in subjects with Gilbert'ssyndrome, if total bilirubin is >2x ULN, measure direct and indirect bilirubinand if direct bilirubin is within normal range, subject may be eligible)

  • No known history of HIV 1 and 2, HTLV-1, or active Hepatitis B or Hepatitis C

  • Must have adequate tissue (ten 5µm unstained formalin-fixed paraffin-embedded (FFPE)sections containing prostate cancer) remaining from pre-treatment diagnosticprostate biopsy for research purposes

  • Patients must be willing to undergo large-volume blood draws (up to 200mL per timepoint) for the investigational component of this trial

  • For those patients who are sexually active, they must be willing to use barriercontraceptive methods during the period of treatment on this trial

  • Patients must be informed of the experimental nature of the study and its potentialrisks, and must sign an IRB-approved written informed consent form indicating suchan

  • Ability to comply with all study procedures and willingness to remain supine for 120minutes during imaging

Exclusion

Exclusion Criteria:

  • Small cell or other variant (non-adenocarcinoma) prostate cancer histology

  • Prior treatment for prostate cancer, including androgen deprivation therapy (ADT),orchiectomy, antiandrogens, ketoconazole, abiraterone acetate or enzalutamide

  • Prior radiation to the prostate

  • Patients may not be receiving other investigational agents or be receivingconcurrent anticancer therapy other than the treatment-prescribed androgendeprivation therapy

  • Treatment with any of the following medications while on study is prohibited,washout period not required except as indicated:

  • Systemic corticosteroids (at doses over the equivalent of 10 mg prednisonedaily) - not permitted within 3 months of registration; inhaled, intranasal ortopical corticosteroids are acceptable

  • PC-SPES

  • Herbal supplements that have been shown to modulate testosterone or androgensignaling (e.g. Saw Palmetto) are not allowed while on study

  • Megestrol

  • Ketoconazole

  • 5-α-reductase inhibitors - patients already taking 5-α-reductase inhibitorsprior to 28 days prior to registration may stay on these agents throughout thecourse of therapy, but these should not be started while patients are on study

  • Diethylstilbesterol

  • Any other non-study hormonal agent or supplement being used with the intent ofcancer treatment

  • Major surgery within 4 weeks of registration is prohibited

  • Active cardiac disease defined as active angina, symptomatic congestive heartfailure, or myocardial infarction within 6 months of registration

  • Patients with known psychological or sociological conditions, addictive disorders orfamily problems, which would preclude compliance with the protocol

  • Patients who have undergone splenectomy

  • Patients must not have other active malignancies other than non-melanoma skincancers or superficial bladder cancer (this includes any non-muscle invasive bladdercancer including Ta, CIS and T1), that have been adequately treated. Subjects with ahistory of other cancers who have been adequately treated and have beenrecurrence-free for > 3 years are eligible.

  • Any other medical intervention or condition, which, in the opinion of the principleinvestigator (PI) or treating physician, could compromise patient safety oradherence with the study requirements over the primary 3-6 month treatment period.

  • Patients who have concurrent enrollment on other phase I, II, or III investigationaltreatment studies cannot be actively receiving treatment and the last dose cannot bewithin 4 weeks.

  • Patients who have received a live vaccine within 14 days prior to the first dose ofstudy treatment. Examples of live vaccines include, but are not limited to, thefollowing: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever,rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenzavaccines for injection are generally killed virus vaccines and are allowed; however,intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and arenot allowed

  • Patients with a history of life-threatening autoimmune disease or active autoimmunedisease that has required systemic treatment in the past 2 years (i.e. with use ofdisease modifying agents, corticosteroids or immunosuppressive drugs). Replacementtherapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapyfor adrenal or pituitary insufficiency, etc.) is not considered a form of systemictreatment

  • Patients with a history of non-infectious pneumonitis that required corticosteroidtreatment, or has current pneumonitis

  • Patients with a history of allergic reactions to the tetanus vaccine

Study Design

Total Participants: 60
Treatment Group(s): 6
Primary Treatment: Fianlimab
Phase: 1/2
Study Start date:
December 16, 2021
Estimated Completion Date:
December 31, 2028

Study Description

The original design of this protocol was to examine the use of a plasmid DNA vaccine encoding Androgen Receptor (AR), alone or with nivolumab, to induce and/or augment therapeutic T-cells following androgen deprivation in participants with newly diagnosed prostate cancer scheduled to undergo prostatectomy in one of three treatment arms. Based on emerging preclinical data that the timing of PD-1 blockade with the first immunization may be critical, and that combining PD-1 and LAG-3 blockade can improve the anti-tumor efficacy of vaccination in murine models of prostate cancer, the trial was amended to include two additional treatment arms testing the timing of PD-1 blockade and the addition of LAG-3 blockade. All participants will receive treatment with degarelix for 8 weeks prior to prostatectomy. In the first part of the study encompassing the first 3 treatment arms, participants will be also be randomized to receive either no additional treatment, a DNA vaccine encoding AR, or a DNA vaccine encoding AR and nivolumab. The additional arms will randomize patients to receive cemiplimab (PD-1 antagonist) with vaccine or cemiplimab with fianlimab (LAG-3 antagonist) and vaccine, with each agent initiated with the first immunization.

Participants receiving vaccination will begin that treatment prior to degarelix, based on preclinical findings that this may be a preferred sequence of treatment. The overall goal is to determine whether a DNA vaccine can augment the number of prostate tumor-specific infiltrating CD8+ T cells elicited with androgen deprivation, and whether this might be further augmented by combination with T-cell checkpoint blockade.

Because these cells should have cytolytic effector function, the primary clinical endpoint is pathological response (pCR and secondarily MRD) at the time of prostatectomy. This endpoint was chosen based on observations from previous clinical trials evaluating androgen deprivation therapies alone in this setting.

Safety will also be a primary objective of the current study, as this vaccine and nivolumab have not been previously used in this early stage population. An additional secondary clinical endpoint will be 1-year PSA progression-free survival, after completion of all therapy, and with evidence of testosterone recovery.

Laboratory and correlative endpoints will include whether vaccination, with or without concurrent T-cell checkpoint blockade, elicits greater numbers of CD8+ tumor-infiltrating lymphocytes, and whether AR-specific prostate tissue-infiltrating CD8+ T cells and persistent systemic immunity are detectable after treatment with vaccination. Other correlative studies will evaluate FLT PET/CT (Arms 1-3) as an investigational means of specifically identifying tumor infiltration by proliferating T cells as an early marker of treatment response, and whether uptake in other normal tissues is associated with autoimmune toxicity. While this is a relatively small trial, given a focus on correlative endpoints, a phase 2 expansion design was chosen to further evaluate the safety and clinical efficacy if pathological responses are observed in the initial part of the trial. If pathological responses exceeding 20% are observed, this will be considered significantly different from what has been historically observed, and would justify proceeding with future larger studies evaluating these combination approaches in the neoadjuvant stage of prostate cancer.

Primary Objectives:

  1. To evaluate the safety of androgen deprivation and pTVG-AR DNA vaccine, alone or in combination with T-cell checkpoint blockade, in patients with newly diagnosed prostate cancer

  2. To determine if pathological complete responses or minimal residual disease (MRD) can occur in patients with prostate cancer treated with androgen deprivation and pTVG-AR, alone or in combination with T-cell checkpoint blockade, prior to definitive surgery

Secondary Clinical Objective:

  1. To estimate 1-year PSA progression-free survival (post-prostatectomy)

  2. To determine whether treatment with androgen deprivation and pTVG-AR DNA vaccine, alone or in combination with T-cell checkpoint blockade, leads to residual cancer burden (RCB) <0.25 cm3 at the time of prostatectomy

  3. To determine the median progression-free survival

Laboratory / Correlative Objectives:

  1. To evaluate whether treatment with pTVG-AR elicits persistent systemic AR-specific Th1-biased T-cell responses

  2. To determine whether treatment with androgen deprivation and pTVG-AR elicits greater numbers of prostate tissue-infiltrating CD8+ T cells compared with androgen deprivation alone, and whether this is augmented with nivolumab, cemiplimab, or cemiplimab and fianlimab

  3. To determine if vaccination with pTVG-AR elicits AR-specific tumor-infiltrating CD8+ T cells

  4. To determine whether PD-1 +/- LAG-3 blockade treatment with androgen deprivation and vaccine increases the frequency of CD8+ T cells with memory and effector function, relative to exhausted phenotype, compared with androgen deprivation and vaccine alone

  5. To determine whether treatment elicits changes detectable by FLT PET imaging (Arms 1-3)

  6. To determine whether LAG-3 with PD-1 blockade and vaccination (Arm 5) elicits greater CD8 T cell infiltration compared to PD-1 blockade and vaccination alone (Arm

  7. To determine whether prostate-tumor infiltrating T cells can be expanded and recognize AR

Connect with a study center

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin 53792
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.